2024 - Moderna: positive opinion from the CHMP in VRS

(CercleFinance.com) – Moderna announces that the CHMP of the European Medicines Agency has adopted a favorable opinion recommending marketing authorization (MA) in the EU for mRESVIA, an mRNA vaccine against respiratory syncytial virus (VRS).

This opinion concerns adults aged 60 years and over against lower respiratory tract diseases caused by RSV infection. The European Commission must now adopt a decision on a marketing authorisation.

The recommendation is based on positive data from the ConquerRSV phase 3 clinical trial, which notably revealed a vaccine efficacy against RSV lower respiratory tract disease of 83.7% with a median follow-up of 3.7 months.

Did you like this article ? Share it with your friends using the buttons below.